Abstract: A method for a method of prophylaxis and/or therapy of neurological conditions in a subject in need thereof includes the step of administrating a recombinant AAV vector to the subject. Also disclosed is the use of the a recombinant AAV vector in the manufacture of a medicament of prophylaxis and/or therapy of neurological conditions in a subject in need thereof. The recombinant AAV vector includes: PHP.eB; a sequence for introducing the expression of human M3 muscarinic DREADD receptor coupled to Gq (hM3Dq); and an inhibitory neuron-specific Distal-less homeobox (Dlx) gene enhancer sequence.

Abstract: The present disclosure relates generally to compositions and methods for modulating cell surface receptor signaling by specifically recruiting membrane phosphatases, in cis, to a spatial proximity of a natural killer cell receptor (NKR) molecule. More particularly, the disclosure provides novel multivalent protein-binding molecules that specifically bind NKR and antagonize the NKR-mediated signaling through recruitment of a phosphatase activity to dephosphorylate the intracellular domain of the NKR. Also provided are compositions and methods useful for producing such molecules, as well as methods for the treatment of health conditions associated with the inhibition of signal transduction mediated by NKRs.

Abstract: The present disclosure relates generally to compositions and methods for modulating cell surface receptor signaling by specifically recruiting membrane phosphatases, in cis, to a spatial proximity of a signal regulatory protein ? (SIRP?) molecule. More particularly, the disclosure provides novel multivalent protein-binding molecules that specifically bind SIRP? and antagonize the SIRP?-mediated signaling through recruitment of a phosphatase activity to dephosphorylate the intracellular domain of SIRP?. Also provided are compositions and methods useful for producing such molecules, methods for promoting maturation dendritic cells and for production of vaccine, as well as methods for the prevention and/or treatment of health conditions associated with the inhibition of signal transduction mediated by SIRP? and/or CD47.